Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Mirabegron relaxes urethral smooth muscle by a dual mechanism involving (3)-adrenoceptor activation and (1)-adrenoceptor blockade

Full text
Author(s):
Alexandre, E. C. [1] ; Kiguti, L. R. [2] ; Calmasini, F. B. [1] ; Silva, F. H. [1] ; da Silva, K. P. [2] ; Ferreira, R. [3] ; Ribeiro, C. A. [2] ; Monica, F. Z. [1] ; Pupo, A. S. [2] ; Antunes, E. [1]
Total Authors: 10
Affiliation:
[1] Univ Campinas UNICAMP, Dept Pharmacol, Campinas, SP - Brazil
[2] Univ Sao Paulo State UNESP, Inst Biosci, Dept Pharmacol, Botucatu, SP - Brazil
[3] Univ Campinas UNICAMP, Fac Med Sci, Hematol & Hemotherapy Ctr, Campinas, SP - Brazil
Total Affiliations: 3
Document type: Journal article
Source: British Journal of Pharmacology; v. 173, n. 3, p. 415-428, FEB 2016.
Web of Science Citations: 20
Abstract

Linked ArticleThis article is commented on by Michel, M. C., pp. 429-430 of this issue. To view this commentary visit . Background and PurposeMirabegron is the first (3)-adrenoceptor agonist approved for treatment of overactive bladder syndrome. This study aimed to investigate the effects of (3)-adrenoceptor agonist mirabegron in mouse urethra. The possibility that mirabegron also exerts (1)-adrenoceptor antagonism was also tested in rat smooth muscle preparations presenting (1A)- (vas deferens and prostate), (1D)- (aorta) and (1B)-adrenoceptors (spleen). Experimental ApproachFunctional assays were carried out in mouse and rat isolated tissues. Competition assays for the specific binding of {[}H-3]prazosin to membrane preparations of HEK-293 cells expressing each of the human (1)-adrenoceptors, as well as -adrenoceptor mRNA expression and cyclic AMP measurements in mouse urethra, were performed. Key ResultsMirabegron produced concentration-dependent urethral relaxations that were shifted to the right by the selective (3)-adrenoceptor antagonist L-748,337 but unaffected by (1)- and (2)-adrenoceptor antagonists (atenolol and ICI-118,551 respectively). Mirabegron-induced relaxations were enhanced by the PDE4 inhibitor rolipram, and the agonist stimulated cAMP synthesis. Mirabegron also produced rightward shifts in urethral contractions induced by the (1)-adrenoceptor agonist phenylephrine. Schild regression analysis revealed that mirabegron behaves as a competitive antagonist of (1)-adrenoceptors in urethra, vas deferens and prostate ((1A)-adrenoceptor, pA(2)5.6) and aorta ((1D)-adrenoceptor, pA(2)5.4) but not in spleen ((1B)-adrenoceptor). The affinities estimated for mirabegron in functional assays were consistent with those estimated in radioligand binding with human recombinant (1A)- and (1D)-adrenoceptors (pK(i)6.0). Conclusion and ImplicationsThe effects of mirabegron in urethral smooth muscle are the result of (3)-adrenoceptor agonism together with (1A) and (1D)-adrenoceptor antagonism. (AU)

FAPESP's process: 14/02196-2 - Role of oxidative stress and soluble guanylate cyclase degradation in micturition dysfunction of insulin resistant obese mice
Grantee:Eduardo Costa Alexandre
Support type: Scholarships in Brazil - Doctorate